Precision RNAi using synthetic shRNAmir target sites.

RNA Interference RNA, Small Interfering / genetics

EGFR KRAS RNAi cancer cancer biology human loss-of-function mouse target validation

Journal

eLife

ISSN: 2050-084X

Titre abrégé: Elife

Pays: England

ID NLM: 101579614

Informations de publication

Date de publication:
08 08 2023

Historique:

medline: 9 8 2023

pubmed: 8 8 2023

entrez: 8 8 2023

Statut: epublish

Résumé

Loss-of-function genetic tools are widely applied for validating therapeutic targets, but their utility remains limited by incomplete on- and uncontrolled off-target effects. We describe artificial RNA interference (ARTi) based on synthetic, ultra-potent, off-target-free shRNAs that enable efficient and inducible suppression of any gene upon introduction of a synthetic target sequence into non-coding transcript regions. ARTi establishes a scalable loss-of-function tool with full control over on- and off-target effects.

Identifiants

DOI: 10.7554/eLife.84792 PMID: 37552050 PMC: PMC10409502

pubmed: 37552050

doi: 10.7554/eLife.84792

pii: 84792

pmc: PMC10409502

doi:

pii:

Substances chimiques

RNA, Small Interfering 0

Banques de données

GEO

['GSE218404', 'GSE218617']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Swiss National Science Foundation

ID : P2BSP3_188110

Pays : Switzerland

Informations de copyright

Déclaration de conflit d'intérêts

TH Full-time employee of Advantage Therapeutics GmbH, AH, MC, JS, FS, AK, KG, AP, SO, NB, JR, PC, MW, RN Full time employee Boehringer Ingelheim, JZ, MH, FA, MS, MF, JZ No competing interests declared

Références

Curr Opin Cell Biol. 2009 Apr;21(2):177-84

pubmed: 19208461

Bioinformatics. 2014 Apr 1;30(7):923-30

pubmed: 24227677

Elife. 2023 Aug 08;12:

pubmed: 37552050

BMC Bioinformatics. 2006 Nov 30;7:520

pubmed: 17137497

N Engl J Med. 2018 Jan 11;378(2):113-125

pubmed: 29151359

Nat Cancer. 2022 Jul;3(7):821-836

pubmed: 35883003

Nucleic Acids Res. 2005 Aug 09;33(14):4527-35

pubmed: 16091630

Science. 2018 May 18;360(6390):800-805

pubmed: 29622725

Life Sci Alliance. 2021 Aug 30;4(11):

pubmed: 34462321

Nat Rev Drug Discov. 2017 Feb;16(2):101-114

pubmed: 27885283

Genome Biol. 2014;15(12):550

pubmed: 25516281

Nucleic Acids Res. 2013 Jan 7;41(1):e9

pubmed: 22941647

Elife. 2017 Jul 10;6:

pubmed: 28691904

Nat Biotechnol. 2003 Jun;21(6):635-7

pubmed: 12754523

Cancer Cell. 2019 Oct 14;36(4):444-457.e7

pubmed: 31588020

Mol Cell. 2011 Mar 18;41(6):733-46

pubmed: 21353615

Nucleic Acids Res. 2015 Apr 20;43(7):e47

pubmed: 25605792

Cell Rep. 2013 Dec 26;5(6):1704-13

pubmed: 24332856

Clin Cancer Res. 2018 Jun 1;24(11):2594-2604

pubmed: 29298799

BMC Bioinformatics. 2019 May 20;20(1):258

pubmed: 31109287

Oncotarget. 2017 Jun 6;8(23):37619-37632

pubmed: 28430577

Nat Biotechnol. 2011 Jan;29(1):79-83

pubmed: 21131983

Nat Rev Mol Cell Biol. 2014 Sep;15(9):591-600

pubmed: 25145850

Nucleic Acids Res. 2011 Sep 1;39(16):7147-60

pubmed: 21609958

BMC Bioinformatics. 2011 Aug 04;12:323

pubmed: 21816040

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7

pubmed: 14769924

Genome Biol. 2014 Feb 03;15(2):R29

pubmed: 24485249

Cell. 2011 Apr 1;145(1):145-58

pubmed: 21458673

Cell Chem Biol. 2017 Sep 21;24(9):1181-1190

pubmed: 28648379

Oncogene. 2008 Aug 7;27(34):4702-11

pubmed: 18408761

Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61

pubmed: 23180760

J Med Chem. 2020 Jan 9;63(1):52-65

pubmed: 31820981

Gastric Cancer. 2019 Nov;22(6):1206-1214

pubmed: 30945121

Bioinformatics. 2013 Jan 1;29(1):15-21

pubmed: 23104886

Nat Rev Genet. 2017 Jan;18(1):24-40

pubmed: 27795562

Nat Rev Clin Oncol. 2022 Oct;19(10):637-655

pubmed: 36028717

Life Sci Alliance. 2020 May 28;3(7):

pubmed: 32467316

Genome Res. 2017 Mar;27(3):491-499

pubmed: 28100584